(Q37942816)

25 August 2017

1 reference

title

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia (English)

1 reference

25 August 2017

1 reference

Mehdi Hamadani

1

1 reference

25 August 2017

Mohamad Mohty

series ordinal

2

1 reference

25 August 2017

Mohamed A Kharfan-Dabaja

series ordinal

3

1 reference

25 August 2017

publication date

1 October 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

237-245

1 reference

Age and acute myeloid leukemia

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Defining the intensity of conditioning regimens: working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

How we approach patient evaluation for hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic cell transplantation in first complete remission versus early relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481101800404

10.1177/107327481101800404

21 January 2018

Identifiers

DOI

0 references

1 reference